- Novartis to acquire ADC developer in a deal worth up to $1.5BThe deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.BioPharma Dive · 22d ago↗ source
- Cancer, immune drugmakers dominate VC funding so far in 2026Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.BioPharma Dive · 22d ago↗ source
- Salk Institute’s president on NIH cuts, ‘all in’ on AI, and the Year of the BrainSAN DIEGO — From the president’s office at the Salk Institute, Gerald Joyce has a quintessential California view of hang gliders soaring over the Pacific Ocean. It’s been a little more turbulent fo…Endpoints